Hofseth Biocare ASA (HOFBF) has released an update.
Hofseth BioCare ASA (HBC) reported a robust first quarter in 2024 with a 17% increase in sales revenue, driven by strong demand for their pet food products and new launches in the Brilliant Petcare line. The company’s R&D efforts have yielded promising results, especially in marine collagen and bioactive peptides, setting the stage for future market growth. Despite a seasonal downturn in the salmon oil market, HBC’s strategic growth led to a record quarter in sales and an improved equity ratio.
For further insights into HOFBF stock, check out TipRanks’ Stock Analysis page.
